Review Article

Triclosan coated sutures: an overview of safety and efficacy in reducing risk of surgical site infection

Sandeep Arvind Sewlikar, Reshmi Sujit Pillai, Nilesh Shailendra Mahajan, Anish Ashok Desai*

Department of Medical Affairs, Clinical Operations and Device Safety, Johnson and Johnson Ltd, Mumbai, MH, India

Received: 17 December 2014
Accepted: 17 January 2015

*Correspondence:
Dr. Anish Ashok Desai,
E-mail: adesai8@its.jnj.com

ABSTRACT

Triclosan, a broad spectrum anti-microbial agent, is in the market for more than 40 years, mainly in personal care products. In 1972, triclosan has been introduced in health care industry, in surgical scrub. The use of triclosan effectively extended other products such as catheters, sutures and urethral stents. We have reviewed toxicity profile of triclosan and clinical publication on Triclosan Coated Suture (TCS). The available toxicity data establishes the acceptable profile of triclosan for using in human being. Till date, 5 systematic reviews and meta-analyses covering 20 randomized control clinical trials have been published, showing the efficacy of TCS in reduction of risk of surgical site infection. Additional, prospective studies are also available to support efficacy of TCS. This compilation may help surgeon to make a conscious decision to use TCS on the basis of evidences.

Keywords: Triclosan, Toxicity, Triclosan coated suture, Surgical site infection

INTRODUCTION

Surgical Site Infection (SSI) is one of the most frequently reported nosocomial infection in hospitalized patients. Considering the health care structure in India mainly in primary health care centers, there is a realistic possibility of SSI leading to major complications such as sepsis and death. It also poses significant health economic burden on patients. Various studies have reported high SSI incidence rate in India. Various guidelines have emphasized on pre and postoperative management of patients to prevent SSI. Antibacterial coated suture could one of the measures to reduce the risk of development of SSI. Triclosan (2,2,4',trichloro-2'-hydroxyphenyl ether) is synthetic broad-spectrum anti-microbial agent present in the market for more than 40 years, mainly in the personal care or consumer products. Currently, triclosan is found in variety of skin care or personal care products such as hand soaps, shower gels, mouth washes, deodorant soaps, toothpastes, etc.

Use of triclosan in health care industry started in 1972, in surgical scrubs. It has also been used in other medical products such as hand subs, skin antiseptics, ointments, impregnated/coated catheters and sutures.

In recent times, many questions have been raised on the triclosan toxicity, its carcinogenicity potential, and efficacy of triclosan mainly in personal and health care product. Additionally, regulatory authorities from developed nation and various eminent societies have been reviewing the safety and efficacy of triclosan in health care and medical devices. At the same time, new clinical evidences are coming into domain, which could definitely change the outlook towards antibacterial suture. The objective of this article is to review the published literature on triclosan toxicity data and various clinical
studies on triclosan coated suture to assess its effectiveness in reducing the risk of SSI.

**TRICLOSAN - SAFETY REVIEW**

**Acute toxicity**

Acute toxicity was evaluated through single dose exposure in animal models thought variety of routes of administration. The LD\(_{50}\) value (lethal dose 50) for animal models is given in Table 1. LD\(_{50}\) value of 2000 to 5000 mg/kg is considered to be non-toxic.\(^{2,4}\)

| Animal model | Route of administration | LD\(_{50}\) value (mg/kg) |
|--------------|-------------------------|--------------------------|
| Mice         | Oral                    | 4350                     |
| Rats         | Oral                    | 3750-5000                |
| Dogs         | Oral                    | >5000                    |
| Rabbits      | Dermal                  | >9300                    |
| Rats         | Subcutaneous            | >14700                   |

**Subchronic toxicity**

Subchronic toxicity has been evaluated for NOEL (no observed effect level) in approximately 90 day oral administration studies in various animal models. NOEL values and the safety factors for each animal model are given in Table 2.\(^{2,3}\) NOEL is highest dose tested in an animal species with no detectable effect. The safety factor of 100-1000 fold is considered as safe for many active ingredients.

| Animal model | Route of administration | Study duration | NOEL (mg/kg) | Safety factor |
|--------------|-------------------------|----------------|--------------|--------------|
| Rat          | Oral                    | 90 days        | 50           | 16667        |
| Dog          | Oral                    | 13 weeks       | 12.5         | 4167         |
| Hamster      | Oral                    | 13 weeks       | 75           | 25000        |
| Baboon       | Oral                    | 1 year         | 30           | 10000        |
| Rabbit       | Oral                    | 13 weeks       | 3            | 1000         |

**Chronic toxicity**

Chronic toxicity studies with long duration exposure to oral administration of triclosan have shown favorable response. Studies were conducted in rat and hamster model. The NOEL (rats – 52 mg/kg for male, 67 mg/kg for females, hamster - 75 mg/kg) values were within the acceptable limit.\(^{2,4}\)

**Carcinogenicity**

No evidence of carcinogenic changes observed in chronic toxicity studies, showing non carcinogenic property of triclosan at NOEL values and with the acceptable safety factor.

**Other toxicity studies**

Various other studies have shown no adverse effects of triclosan on pregnancy and reproductive potential. Triclosan is also proved as not potential to develop teratogenicity, mutagenicity and genotoxicities at various NOEL values observed in animal toxicity studies.\(^{2}\)

**TRICLOSAN COATED SUTURE - ASSESSMENT OF SAFETY**

The triclosan content on various triclosan coated sutures is given in the Table 3. Barbolt TA has evaluated the gradual exposure of triclosan (related to triclosan dissipation profile for each suture) and worst case scenario ‘immediate exposure’.\(^{2}\) The toxicity due to triclosan coated suture are considered to be low due low exposure levels, rapid metabolism and excretion, and lack of accumulation over time.\(^{2}\)

Considering the dissipation profile of triclosan for each suture type and worst case scenario of 5 m of a 2-0 suture with 472 μg triclosan/m (270 for EU and India) for vicryl\(^{TM}\) Plus and 2360 μg/m for PDS\(^{TM}\) plus and monocryl\(^{TM}\) plus, the maximal single-day exposure to triclosan was calculated to be 0.03, 0.09 and 0.08 mg/kg body weight.\(^{2,4}\) The safety margin would be in the range of 160 to 2500, good enough to consider triclosan safe.

| Suture          | Polymer          | % dissipation in first 24 hours | Triclosan content on suture material | Safety margin |
|-----------------|------------------|--------------------------------|-------------------------------------|---------------|
| Vicryl\(^{TM}\) plus | Poliglecaprone 25 | 41                             | < 2360 μg/m                          | 160-94        |
| VICRYL\(^{TM}\) plus | Poliglecaprone 25 | 41                             | < 2360 μg/m                          | 160-94        |
| VC-520 PLUS     | Poliglecaprone 25 | 41                             | < 2360 μg/m                          | 160-94        |

Thus, Barbolt TA highlighted the extensive clinical experience with triclosan coated suture, availability of favorable toxicity study data and non-carcinogenic potential, precludes the need to conduct genotoxicity studies and other toxicity studies.\(^{2}\)
TRICLOSAN - MECHANISM OF ACTION AND ANTIBACTERIAL PROFILE

Triclosan exhibits its bactericidal property by inhibiting FabI gene which encodes the enoyl-acyl carrier protein reductase enzyme (ENR). It is essential in fatty acid biosynthesis, which is inhibited by triclosan. Triclosan disrupts the cell membrane causing cell contents to leak. 

Triclosan has bactericidal activity against most of the microorganisms primarily responsible for SSI.

Table 4: Microorganisms susceptible to triclosan coated suture using zone of inhibition studies.

| Microorganisms susceptible to triclosan coated suture | NTCS | TCS |
|-------------------------------------------------------|------|-----|
| Staphylococcus aureus                                 |      |     |
| Methicillin resistant Staphylococcus aureus (MRSA)    |      |     |
| Staphylococcus epidermidis                            |      |     |
| Methicillin resistant Staphylococcus epidermidis (MRSE)|      |     |
| Eeschirichia coli                                     |      |     |
| Klebsiella pneumoniae                                  |      |     |

Some of the bacteria such as Pseudomonas aeruginosa, Acinetobacter requires high concentration of triclosan for the bactericidal effect. Leaper D et al. pointed out that due to multi-drug efflux pumps that remove triclosan from cell also distinct versions of the ENR, Pseudomonas aeruginosa shows innate resistance to triclosan.

BACTERIAL RESISTANCE

Although various studies have shown resistance to triclosan, but these studies basically are the laboratory studies. However, resistance to triclosan has not been demonstrated in various clinical studies or from epidemiological data. Hence, there is no clinical evidence for triclosan resistance.

ZONE OF INHIBITION AND RELATED STUDIES

Using zone of inhibition studies, antibacterial sutures shown to inhibit bacterial colonization of S. aureus (SA), MRSA, S. epidermidis, MRSE, E. coli and K. pneumonia (Table 4). Sarkar S et al. have conducted in-vitro zone of inhibition studies for triclosan coated and uncoated suture against the bacteria isolated from SSI. In addition to above bacteria, other bacteria such as acinetobacter, Coagulase negative staphylococcus, Proteus and Pseudomonas. Zone of inhibition was observed in all bacterial plate except for Pseudomonas and Acinetobacter. Edmiston CE et al. has showed substantial reduction in in both gram-positive and gram-negative bacterial adherence to triclosan coated polyglyactin 910 (braided) suture compared with non triclosan coated suture, in an in vitro microbiologic model (Standardized cultures (2.0 log) colony forming units/mL and 5.0 log) colony forming units/mL of three clinical strains, S. aureus (MRSA), S. epidermidis (biofilm-positive) and Escherichia coli [extended-spectrum beta-lactamase (ESBL)-producer]. These results were similar to earlier zone of inhibition study conducted for triclosan coated polyglactine 910 sutures.

In another in vitro study, triclosan coated polydioxanone sutures found to be effective against S. aureus, MRSA, S. epidermidis, MRSE, K. pneumoniae, and E. coli. Additionally, antibacterial activity was lasted for 17-23 days till the suture dissolved. In animal models, it was found that TCS inhibited in vivo colonization of bacteria compared with the non-coated suture (99.9% reduction in S. aureus and a 90% reduction in E. coli). The same author group also published in vivo antibacterial efficacy of triclosan coated poliglecaprone 25 suture.

TRICLOSAN COATED SUTURE - CLINICAL STUDIES PUBLISHED

Since the introduction of triclosan coated sutures, many clinical studies have been published in varied therapeutic area. It includes systematic reviews and meta-analyses, Randomized controlled Clinical Trials (RCTs), and other clinical trials such as cohort studies, case controlled studies and case series. The evidences are published in various therapeutic segment e.g. general surgeries, urosurgery, breast surgery, gynecological procedures, oncology surgery, cardiac and vascular surgery, orthopedic surgery, ENT surgery, etc. The brief information and the study outcome are given in Table 5, 6 and 7.

Table 5: Triclosan coated sutures: published studies.

| Publication type | N |
|------------------|---|
| Systematic reviews and meta-analyses | 5 |
| Randomized controlled clinical trials | 20 |
| Clinical studies (Other than RCTs) | 10 |

Table 6: Triclosan coated sutures: Systematic review and meta-analyses - Level 1a evidence.

| First author (year) | RCTs | Sample size | OR  | RR  | P value |
|---------------------|------|-------------|-----|-----|---------|
| Daoud FC (2014)     | 10   | 2323        | 0.67| 0.00053 |
| Edmiston CE (2013)  | 11   | 1654        | 0.73| 0.005 |
| Wang ZX (2013)      | 12   | 1726        | 0.70| <0.001 |
| Sajid MS (2013)     | 13   | 760         | 0.61| -    | 0.04 |
| Chang WK (2012)     | 14   | 393         | 0.77| 0.45 and 0.39 |

OR-Odds ratio, RR-Relative risk, TCS-Triclosan coated suture, NTCS-Non triclosan coated suture.
Table 7: Triclosan coated sutures: randomized controlled clinical trials.

| Study, (year) | Procedure                      | Follow up period | Sample size | Results (SSI rate) |
|---------------|--------------------------------|------------------|-------------|--------------------|
| Ford, 2005    | General surgery                | 30 days          | TCS: 98 NTCS: 49 | TCS: 3/98 NTCS: 0/49 |
| Rozzelle, 2008| CSF shunt                      | 6 months         | TCS: 46 NTCS: 38 | TCS: 2/46 NTCS: 8/38 |
| Mingmalairak, 2009 | Appendectomy        | 12 months        | TCS: 50 NTCS: 50 | TCS: 5/50 NTCS: 4/50 |
| Zhuang, 2009  | Laparotomy                     | 12-14 months     | TCS: 150 NTCS: 300 (2 types) | TCS: 0/150 NTCS(1): 3/150, NTCS(2): 15/150 |
| Zhang, 2011   | Mastectomy                     | 90 days          | TCS: 50 NTCS: 50 | TCS: 2/46 NTCS: 5/43 |
| Galal, 2011   | General surgery                | 12 months        | TCS: 230 NTCS: 220 | TCS: 17/230 NTCS: 33/220 |
| Rasic, 2011   | Colorectal                     | Not given        | TCS: 91 NTCS: 93 | TCS: 4/91 NTCS: 12/93 |
| Baracs, 2011  | Colorectal                     | 30 days          | TCS: 188 NTCS: 197 | TCS: 23/188 NTCS: 24/197 |
| Williams, 2011| Breast cancer                  | 6 weeks          | TCS: 75 NTCS: 75 | TCS: 10/66 NTCS: 14/61 |
| Turtiainen, 2012 | Lower limb revascularization | 1 month         | TCS: 139 NTCS: 137 | TCS: 31/139 NTCS: 30/137 |
| Seim, 2012    | CABG                           | 4 weeks          | TCS: 160 NTCS: 163 | TCS: 16/160 NTCS: 17/163 |
| Isik 2012     | Cardiac surgery                | 30 days          | TCS: 170 NTCS: 340 | TCS: 4/170 NTCS: 12/340 |
| Nakamura, 2013 | Colorectal                  | 30 days          | TCS: 206 NTCS: 204 | TCS: 9/206 NTCS: 19/204 |
| Thimour-Bergstrom, 2013 | CABG                     | 60 days          | TCS: 184 NTCS: 190 | TCS: 23/184 NTCS: 38/190 |
| Justinger, 2013 | Laparotomy              | 2 weeks          | TCS: 485 NTCS: 372 | TCS: 31/485 NTCS: 42/371 |
| DeFazio, 2005 | Umbilical incision         | 6 weeks          | TCS: 43 NTCS: 50 | TCS: 4/43 NTCS: 4/50 |
| Deliaert, 2009 | Breast surgery               | 4 weeks          | TCS: 26 NTCS: 26 | TCS: 0/26 NTCS: 0/26 |
| Khachatryan, 2011 | Abdominal surgery    | Not provided    | TCS: 65 NTCS: 68 | TCS: 6/65 NTCS: 14/65 |
| Mattavelli, 2011 | Colorectal surgery           | 30 days          | TCS: 108 NTCS: 109 | TCS: 11/108 NTCS: 12/109 |
| Singh, 2010   | CABG                           | 30 days          | TCS: 50 NTCS: 50 | TCS: 6/50 NTCS: 16/50 |

The brief information and the study outcome are given in Table 5, 6 and 7. The meta-analyses published have been discussed in detail. Recent meta-analyses published in last couple of years discussed in detail here.

Daoud FC et al. (2014):10 The main objective of the Systematic Literature Review (SLR) was to assess the robustness of study results by applying more stringent statistical tests compared to first meta-analysis, to determine the efficacy of TCS in reduction of risk of SSI.

Table 8: Daoud FC et al.: 13 steps analytical strategy.

| Risk ratio to measure effect | Publication bias |
|-----------------------------|------------------|
| Heterogeneity between trials | Random effects pooled relative risk (RR) |
| Sensitivity analysis of robustness | Blinding methodology followed in RCTs |
| Differences in SSI diagnostic methodologies in each RCTS | Suture materials |
| CDC incision class           | Incision depth or site |
| Operation type               | Confounding relationship between RR and SSI incidence rate |
| Evaluation of certainty of triclosan effect based on robustness of results of first 12 steps | |

The secondary objectives were to assess potential bias or confounding factors which could invalidate the triclosan effect in the pooled RCTs. RCTs included were selected on criteria used to assess quality of study and publication bias. A rigorous 13 step analytical strategies were used to meet the objectives of SLR (Table 8). The data from 15 RCTs totaling 4000 patients (TCS=2323) and NTCS=2477) were analyzed. Use of TCS was associated with a decrease in SSI in selected patient populations (RR = 0.67; P = 0.00053), means 33% reduction in risk of developing SSI. TCS showed highly statistical significant results in lowering risk of SSI. TCS was effective in clean (P = 0.001), clean-contaminated (P = 0.010), and contaminated incisions (P = 0.026). SLR result was robust to the removal of three RCTs. SLR showed highly statistical significant results favoring TCS in reduction of risk of SSI and robustness of clinical results - relative risk independent of confounding factors.

Edmiston CE et al. (2013):11 The meta-analysis was conducted in response to recently published systematic reviews and meta-analysis which have suggested about no benefits of anti-microbial coated suture in reducing the Surgical Site Infections (SSI). Authors have highlighted poor selection of available RCT and low patient numbers for these meta-analyses. The primary endpoint of the systematic review was to determine the ratio of patients who developed an SSI in two comparative groups: closure with TCS versus NTCS sutures. Total 13 RCTs
were selected, totaling 3568 patients (TCS=1654) and NTCS=1994). Stringent criteria was applied for selection of RCTs such as protocol with defined objective, accurate SSI definition, specified patient population, proper randomization procedure, study design which enables unbiased comparison between two groups, lost to follow up patients <10%, ethical conduct of study, etc. Publication bias (fixed - assuming same patient population and random effect - assuming clinically heterogeneous patient population), heterogeneity and sensitivity analysis was considered to check the robustness of the model used. Use of TCS was associated with a decrease in SSIs in selected patient populations (fixed effect: RR = 0.734; P = 0.005; random-effect: RR = 0.693; P = 0.011), means 27-31% reduction in risk of developing SSIs. No publication bias was detected (Egger intercept test: P = 0.145).

Wang ZX et al. (2013):12 Total 17 RCTs were selected for the meta-analysis, covering 3720 patients (TCS=1726) and NTCS=1994). The meta-analysis was performed in adherence to the guidelines outlined in the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. All 17 studies selected were assessed independently by 2 investigators. Risk of bias and methodological quality of included studies were assessed using the Cochrane Collaboration tool for assessing risk of bias. Publication bias also was assessed by using Funnel plots. Results favored TCS with a pooled RR of 0.70 (P <0.001) without statistical heterogeneity (P for Q test = 0.129, I²=29 per cent), means TCS provided significant advantage in reducing the rate of SSI by 30%. Subgroup analysis indicates statistical significant results of reduction in SSI by using TCS in adult patients, abdominal surgery and clean or clean contaminated wounds. The advantage of TCS over conventional sutures was consistent regardless of length of follow-up. The qualities of the included studies were acceptable with moderate risk of bias and no evidence for significant publication bias was noted.

Twenty RCTs were evaluated in these meta-analyses.15-34 The brief information on sample size, procedures and SSI rate reported in these RCTs has given in Table 7. Justinger C et al. has published large retrospective study of 2088 patients in mid laparotomy. The results showed the decrease in number of SSIs (TCS: 4.9%, NTCS: 10.8%, P <0.001) for abdominal wall closure.35 In another prospective comparative study in transverse laparotomy for hepatobiliary resections (n=839), TCS showed significant reduction in SSI compared to NTCS arm (4.3% vs. 9.2%, P = 0.05).36 In spinal surgery, TCS found to be effective in reduction of wound infection (0.5% vs. 3.9%, p=0.020).37 A recent paper on gastric cancer surgery via midline laparotomy also showed the reduction of SSI cases in abdominal wall closure.38 Other prospective studies in digestive tract surgery,39 breast cancer surgeries,40 abdominal surgeries,41 and cardiac surgeries (sternal site infections).42 TCS was found to be effective in minimizing the risk of development of SSI post-surgery.

**SUMMARY**

Wide range of published evidences is available for toxicity profile of triclosan, antibacterial profile and clinical effectiveness of TCS. Hence, it assures use of TCS in minimizing the risk of SSI. This effort is an attempt to draw attention to the continuous publication around TCS and reemphasize the efficacy and safety parameter as in these published clinical evidences. This compilation may help surgeon to make a conscious decision to use TCS on the basis of evidences.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**

1. Ramasubramanian V, Iyer V, Sewlikar S, Desai A. Epidemiology of healthcare acquired infection – An Indian perspective on surgical site infection and catheter related blood stream infection. Indian J Basic Appl Med Res. 2014 Sep;3(4):46-63.
2. Barbolt TA. Chemistry and safety of triclosan, and its use as an antimicrobial coating on coated vicryl* plus antibacterial suture (coated polygactin 910 suture with triclosan). Surg Infect (Larchmt). 2002;3(Suppl 1):S45-53.
3. Jones RD, Jampani HB, Newman JL, Lee AS. Triclosan: a review of effectiveness and safety in health care settings. Am J Infect Control. 2000 Apr;28(2):184-96.
4. Leaper D, Assadadian O, Hubner NO, McBain A, Barbolt T, Rothenburger S, et al. Antimicrobial sutures and prevention of surgical site infection: assessment of the safety of the antiseptic triclosan. Int Wound J. 2011 Dec;8(6):556-66.
5. SenGupta M, Banerjee D, Sengupta M, Sarkar S, Nag S, Singh M. In vitro efficacy of triclosan coated polygactin 910 suture against common bacterial pathogen causing surgical site infection. Int J Infect Control. 2014;10(2):1-6.
6. Edmiston CE, Seabrook GR, Goheen MP, Krepel CJ, Johnson CP, Lewis BD, et al. Bacterial adherence to surgical sutures: can antibacterial-coated sutures reduce the risk of microbial contamination? J Am Coll Surg. 2006 Oct;203(4):481-9.
7. Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluation of coated vicryl* plus antibacterial suture (coated polygactin 910 with triclosan) using zone of inhibition assays. Surg Infect (Larchmt). 2002;3(Suppl 1):S79-87.
8. Ming X, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS plus (polidioxanone with triclosan) suture. Surg Infect (Larchmt). 2008 Aug;9(4):451-7.
9. Ming X, Nichols M, Rothenburger S. In vivo antibacterial efficacy of MONOCRYL plus antibacterial suture (Poliglecaprone 25 with triclosan). Surg Infect (Larchmt). 2007 Apr;8(2):209-14.

10. Daoud FC, Edmiston CE Jr, Leaper D. Meta-analysis of prevention of surgical site infections following incision closure with triclosan-coated sutures: robustness to new evidence. Surg Infect (Larchmt). 2014 Jun;15(3):165-81.

11. Edmiston CE Jr, Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimicrobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections? A meta-analysis. Surgery. 2014 Feb;155(2):362-3.

12. Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2013 Mar;100(4):465-73.

13. Sajid MS, Craciunas L, Sains P, Singh KK, Baig MK. Use of antibacterial sutures for skin closure in controlling surgical site infections: a systematic review of published randomized, controlled trials. Gastroenterol Rep. 2013;1:1-9.

14. Chang WK, Sririvasa S, Morton R, Hill AG. Triclosan-impregnated sutures to decrease surgical site infections: systematic review and meta-analysis of randomized trials. Ann Surg. 2012 May;255(5):854-9.

15. Ford HR, Jones P, Gaines B, Reblock K, Simpkins DL. Intraoperative handling and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated VICRYL suture (coated polyglactin 910 suture). Surg Infect (Larchmt). 2005;6(3):313-21.

16. Rozzelle CJ, Leonardo J, Li V. Antimicrobial suture wound closure for cerebrospinal fluid shunt surgery: a prospective, double-blinded, randomized controlled trial. J Neurosurg Pediatr. 2008 Aug;2(2):111-7.

17. Mingmalairak C, Unghbakorn P, Paocharoen V. Efficacy of antimicrobial coating suture coated polyglactin 910 with triclosan (Vicryl plus) compared with polyglactin 910 (Vicryl) in reduced surgical site infection of appendicitis, double blind randomized control trial, preliminary safety report. J Med Assoc Thai. 2009 Jun;92(6):770-5.

18. Zhuang CP, Cai GY, Wang YQ. Comparison of two absorbable sutures in abdominal wall incision. J Clin Rehabil Tissue Engin Res. 2009;13(21):4045-8.

19. Zhang ZT, Zhang HW, Fang XD, Wang LM, Li XX, Li YF, et al. Cosmetic outcome and surgical site infection rates of antibacterial absorbable (Polyglactin 910) suture compared to Chinese silk suture in breast cancer surgery: a randomized pilot research. Chin Med J (Engl). 2011 Mar;124(5):719-24.

20. Galal I, El-Hindawy K. Impact of using triclosan-antibacterial sutures on incidence of surgical site infection. Am J Surg. 2011 Aug;202(2):133-8.

21. Rasić Z, Schwarz D, Adam VN, Sever M, Lojo N, Rasić D, et al. Efficacy of antimicrobial triclosan-coated polyglactin 910 (Vicryl® plus) suture for closure of the abdominal wall after colorectal surgery. Coll Antropol. 2011 Jun;35(2):439-43.

22. Baracs J, Huszár O, Sajjadi SG, Horváth OP. Surgical site infections after abdominal closure in colorectal surgery using triclosan-coated absorbable suture (PDS plus) vs. uncoated sutures (PDS II): a randomized multicenter study. Surg Infect (Larchmt). 2011 Dec;12(6):483-9.

23. Williams N, Sweetland H, Goyal S, Ivins N, Leaper DJ. Randomized trial of antimicrobial-coated sutures to prevent surgical site infection after breast cancer surgery. Surg Infect (Larchmt). 2011 Dec;12(6):469-74.

24. Turtiainen J, Saimanen EI, Mäkinen KT, Nykänen AI, Venermo MA, Uurto IT, et al. Effect of triclosan-coated sutures on the incidence of surgical wound infection after lower limb revascularization surgery: a randomized controlled trial. World J Surg. 2012 Oct;36(10):2528-34.

25. Seim BE, Tønnessen T, Woldbaek PR. Triclosan-coated sutures do not reduce leg wound infections after coronary artery bypass grafting. Interact Cardiovasc Thorac Surg. 2012 Sep;15(3):411-5.

26. Isik I, Selimen D, Senay S, Alhan C. Efficiency of antibacterial suture material in cardiac surgery: a double-blind randomized prospective study. Heart Surg Forum. 2012 Feb;15(1):E40-5.

27. Nakamura T, Kashimura N, Noji T, Suzuki O, Ambo Y, Nakamura F, et al. Triclosan-coated sutures reduce the incidence of wound infections and the costs after colorectal surgery: a randomized controlled trial. Surgery. 2013 Apr;153(4):876-83.

28. Thimour-Bergström L, Roman-Emanuel C, Scherstén H, Friberg Ö, Gudbjartsson T, Jeppsson A. Triclosan-coated sutures reduce surgical site infection after open vein harvesting in coronary artery bypass grafting patients: a randomized controlled trial. Eur J Cardiothorac Surg. 2013 Nov;44(5):931-8.

29. Justinger C, Slotta JE, Ningel S, Gräber S, Kollmar O, Schilling MK. Surgical-site infection after abdominal wall closure with triclosan-impregnated polydioxanone sutures: results of a randomized clinical pathway facilitated trial. Surgery. 2013 Sep;154(3):589-95.

30. DeFazio A, Datta MS, Nezhat C. Does the use of vicryl plus antibacterial suture decrease the incidence of umbilical infection when compared to vicryl suture? J Minim Invasive Gynecol. 2005 Sept;Oct;12(5 Suppl):S38.

31. Deliaert AE, Van den Kerckhove E, Tuinder S, Fieuws S, Sawor JH, Meesters-Caberg MA, et al. The effect of triclosan-coated sutures in wound healing. A double blind randomised prospective
pilot study. J Plast Reconstr Aesthet Surg. 2009 Jun;62(6):771-3.
32. Khachatryan N, Dibirov M, Omelyanovsky V, Chupalov M, Gasanova G. Prevention of postoperative infections in abdominal surgery using reabsorbable suture with antibacterial activity (Vicryl plus) versus reabsorbable standard sutures. Surg Infect (Larchmt). 2011;12(2):A13-4.
33. Mattavelli I, Nespoli L, Alfieri S, Cantore F, Sebastian-Douglas S, Cobianchi L, et al. Triclosan-coated suture to reduce surgical site infection after colorectal surgery. Surg Infect. 2011;12(2):A14-5.
34. Singh H, Emmert MY, Sakaguchi H, Neng Lee CH, Kofidis TH. Antibacterial suture reduces surgical site infections in coronary artery bypass grafting. Heart Surg Forum. 2010;13(Suppl 1):S85.
35. Justinger C, Moussavian MR, Schlueter C, Kopp B, Kollmar O, Schilling MK. Antibiotic coating of abdominal closure sutures and wound infection. Surgery. 2009;145(3):330-4.
36. Justinger C, Schuld J, Sperling J, Kollmar O, Richter S, Schilling MK. Triclosan-coated sutures reduce wound infections after hepatobiliary surgery - a prospective non-randomized clinical pathway driven study. Langenbecks Arch Surg. 2011;396(6):845-50.
37. Ueno M, Saito W, Yamagata M, Imura T, Inoue G, Nakazawa T, et al. Triclosan-coated sutures reduce wound infections after spinal surgery: a retrospective, nonrandomized, clinical study. Spine J. 2013 Aug;27 pii: S1529-9430(13)00721-3.
38. Jung KH, Oh SJ, Choi KK, Kim SM, Choi MG, Lee JH, et al. Effect of triclosan-coated sutures on surgical site infection after gastric cancer surgery via midline laparotomy. Ann Surg Treat Res. 2014 Dec;87(6):311-8.
39. Hoshino S, Yoshida Y, Tanimura S, Yamauchi Y, Noritomi T, Yamashita Y. A study of the efficacy of antibacterial sutures for surgical site infection: a retrospective controlled trial. Int Surg. 2013 Apr-Jun;98(2):129-32.
40. Laas E, Poilroux C, Bézu C, Coutant C, Uzan S, Rouzier R, et al. Antibacterial-coated suture in reducing surgical site infection in breast surgery: a prospective study. Int J Breast Cancer. 2012;2012:819578.
41. Justinger C, Slotta JE, Schilling MK. Incisional hernia after abdominal closure with slowly absorbable versus fast absorbable, antibacterial-coated sutures. Surgery. 2012 Mar;151(3):398-403.
42. Fleck T, Moidl R, Blacky A, Fleck M, Wolner E, Grabenwoger M, et al. Triclosan-coated sutures for the reduction of sternal wound infections: economic considerations. Ann Thorac Surg. 2007;84(1):232-6.
43. Ethicon. Vicryl™ plus, PDS™ plus, Monocryl™ plus - respective product Instruction for use document, 2010-2015. Available at: www.ethicon.com.

DOI: 10.5455/2349-2902.isj20150201
Cite this article as: Sewlikar SA, Pillai RS, Mahajan NS, Desai AA. Triclosan coated sutures: an overview of safety and efficacy in reducing risk of surgical site infection. Int Surg J 2015;2:xxx-xx.